Pun K K, Yeung C K, Ho P W, Lin H J, Chan M K, Yeung R T
Clin Nephrol. 1984 Apr;21(4):235-40.
Hypoglycemia is frequently reported in hemodialysis patients on propranolol. We studied the influence of propranolol on carbohydrate metabolism in sixteen hemodialysis patients (eight on propranolol and eight not) with pre-dialysis oral glucose tolerance tests (OGTT) and pre- and post-dialysis glucagon tests. Propranolol was shown to have significant suppressive effect on the insulin response during OGTT. With glucagon challenge pre- and post-dialysis, despite a similar cAMP response, patients on propranolol had significantly lower glucose response than those not receiving propranolol and it is postulated that this is due to post-receptor post-cAMP inhibition of hepatic glycogenolysis. Moreover, while the glucose response in patients not on propranolol significantly increased after dialysis, no significant change was found in patients on propranolol. The significantly higher C-peptide, insulin and cAMP responses to glucagon challenge in the hemodialysis patients as compared to normal controls may be due to delayed clearance of glucagon, and the further increased responses after dialysis may be due to the removal of a dialyzable factor suppressing these responses.
血液透析患者使用普萘洛尔时低血糖情况屡有报道。我们对16例血液透析患者(8例使用普萘洛尔,8例未使用)进行了透析前口服葡萄糖耐量试验(OGTT)以及透析前后胰高血糖素试验,以研究普萘洛尔对碳水化合物代谢的影响。结果显示,普萘洛尔对OGTT期间的胰岛素反应有显著抑制作用。在透析前后进行胰高血糖素激发试验时,尽管环磷酸腺苷(cAMP)反应相似,但使用普萘洛尔的患者血糖反应明显低于未使用普萘洛尔的患者,据推测这是由于cAMP作用后受体对肝糖原分解的抑制。此外,未使用普萘洛尔的患者透析后血糖反应显著增加,而使用普萘洛尔的患者未发现显著变化。与正常对照组相比,血液透析患者对胰高血糖素激发试验的C肽、胰岛素和cAMP反应显著更高,这可能是由于胰高血糖素清除延迟所致,透析后反应进一步增加可能是由于去除了抑制这些反应的可透析因子。